The present invention includes methods and kits for the diagnosing a neurological disease within primary care settings comprising: obtaining a blood test sample from a subject, measuring IL-7 and TNFα biomarkers in the blood sample, comparing the level of the one or a combination of biomarkers and neurocognitive screening tests with the level of a corresponding one or combination of biomarkers in a normal blood sample and neurocognitive screening tests, and predicting that an increase in the level of the blood test sample in relation to that of the normal blood sample indicates that the subject is likely to have a neurological disease.
Legal claims defining the scope of protection, as filed with the USPTO.
2. The method of claim 1, wherein the subject is determined to suffer from cognitive impairment for having a lower score in at least one neurocognitive evaluation selected from the group consisting of a clock drawing test, verbal fluency test, trail making test, list learning test, sleep disturbances, visual hallucinations, behavioral disturbances, motor disturbances, and any combinations thereof, as compared to a normal subject.
3. The method of claim 1, wherein the blood sample is a serum or a plasma sample.
6. The method of claim 5, wherein the subject is determined to suffer from cognitive impairment for having a lower score in at least one neurocognitive evaluation selected from the group consisting of clock drawing test, verbal fluency test, trail making test, list learning test, sleep disturbances, visual hallucinations, behavioral disturbances, motor disturbances, and any combinations thereof, as compared to a normal subject.
Cooperative Patent Classification codes for this invention. Click any code to explore related patents in that topic.
July 9, 2014
December 13, 2022
Browse 5M+ US patents with plain-English claim translations and AI-generated analysis.